United Theranostics
Seth Van Voorhees is a seasoned financial executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Chief Financial Officer at United Theranostics since September 2024, Seth is instrumental in advancing innovative radiopharmaceutical therapies for precision cancer care. Prior to this role, Seth held the position of Chief Financial Officer and Treasurer at NRx Pharmaceuticals, where efforts focused on developing treatments for bipolar depression. Additional leadership roles include Chief Financial Officer for PDS Biotechnology, Research Frontiers Inc., and American Pacific Corporation, as well as serving as Principal at Case Advisors LLC. Seth holds an MBA in Finance from Columbia Business School and a Ph.D. in Chemistry from the University of Pennsylvania, complemented by a Bachelor's degree in Chemistry from Stony Brook University.
This person is not in any teams
United Theranostics
Our practices focus on the treatment of patients with internal radiation therapy, primarily in the setting of oncologic disease. We offer a safe and comfortable environment in the outpatient setting to receive specialized current and emerging theranostics; targeted radiopharmaceutical therapies. Current indications we treat are thyroid cancer, metastatic prostate cancer, and metastatic neuroendocrine cancer. We work in close collaboration to coordinate your care together with your oncologist, endocrinologist, urologist or other referring provider.